| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Quinacrine 2HCl (Mepacrine; SN-390) is a lipophilic cationic drug with multiple actions that is commonly used as an anti-protozoal agent. Quinacrine dihydrochloride is a non-specific PLA2 (phospholipase A2) inhibitor. Quinacrine, Dihydrochloride acts as an AChR (acetylcholine receptor) antagonist. Quinacrine dihydrochloride suppresses glibenclamide-sensitive K+-currents (IC50 = 4.4 μM). This compound also inhibits MAO (monoamine oxidase). Quinacrine, Dihydrochloride is an inhibitor of cPLA2, MAO-A and MAO-B.
| ln Vitro |
Quinacrine (5–20 μM; 24 hours) stops SGC-7901 cells from growing [1]. Quinacrine (7.5 and 15 μM; 24 hours) causes SGC-7901 cells to go into apoptosis. This process is linked to signaling pathways that are dependent on the mitochondria and include p53 upregulation and caspase-3 activation [1]. After being treated with quinacrine (15 μM; 24 hours), pro-apoptotic proteins such as p53, Bax, and cytochrome c were considerably elevated while levels of the anti-apoptotic protein Bcl-2 were lowered. This led to an increase in the ratio of Bax/Bcl-2, which is favorable for cell apoptosis[1].
|
|---|---|
| ln Vivo |
Quinacrine (three times a week for two weeks at a dose of 100 mg/kg) enhanced the median survival time (MST) and significantly reduced circulating blasts on days 30 and 31. In treated rats, quinacrine did not cause a reduction in body weight at the tested levels [2].
|
| Cell Assay |
Cell Viability Assay [1]
Cell Types: SGC-7901 Cell Tested Concentrations: 0, 5, 10, 15 and 20 μM Incubation Duration: 24 hrs (hours) Experimental Results: Cell viability was inhibited in a dose-dependent manner with an average IC50 value of 16.18 μM. Apoptosis analysis [1] Cell Types: SGC-7901 Cell Tested Concentrations: 7.5 and 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: Compared with the control group, the percentage of apoptotic cells (including early and late apoptosis) increased to 26.30%. 3.37%. Western Blot Analysis [1] Cell Types: SGC-7901 Cell Tested Concentrations: 15 μM Incubation Duration: 24 hrs (hours) Experimental Results: The relative amount of cytochrome c protein was increased from 0.10 to 0.24. The relative amount of p53 protein increased Dramatically, from 0.06 to 0.19. The Bax/Bcl-2 ratio increased sharply from 1.21 to 2.59. |
| Animal Protocol |
Animal/Disease Models: Acute myeloid leukemia (AML) female SCID mouse-PS model [2]
Doses: 100 mg/kg Route of Administration: po (oral gavage); 3 times a week for two consecutive weeks Experimental Results: On the first In an in vivo mouse study of AML, evaluation of circulating leukemia cells (expressed as a percentage of white blood cells (WBC)) detected in blood samples at day 30/31 demonstrated that 72% were human tumor cells in control mice, whereas In mice treated with quinacrine, the rate was only 2.2%. The MST of control mice was 34 days, while the MST of quinacrine-treated mice was 46 days. |
| References |
[1]. Xiaoyang Wu, et al. Quinacrine Inhibits Cell Growth and Induces Apoptosis in Human Gastric Cancer Cell Line SGC-7901. Curr Ther Res Clin Exp. 2012 Feb;73(1-2):52-64.
[2]. Anna Eriksson, et al. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. Leuk Res. 2017 Dec;63:41-46. |
| Molecular Formula |
C23H30CLN3O.2HCL
|
|
|---|---|---|
| Molecular Weight |
472.88
|
|
| CAS # |
69-05-6
|
|
| Related CAS # |
l-Atabrine dihydrochloride;56100-42-6;d-Atabrine dihydrochloride;56100-41-5;Quinacrine;83-89-6;Quinacrine hydrochloride hydrate;6151-30-0
|
|
| SMILES |
ClC1C([H])=C([H])C2=C(C=1[H])N=C1C([H])=C([H])C(=C([H])C1=C2N([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])[H])OC([H])([H])[H].Cl[H].Cl[H]
|
|
| InChi Key |
UDKVBVICMUEIKS-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C23H30ClN3O.2ClH/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23;;/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26);2*1H
|
|
| Chemical Name |
N4-(6-chloro-2-methoxyacridin-9-yl)-N1,N1-diethylpentane-1,4-diamine dihydrochloride
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1147 mL | 10.5735 mL | 21.1470 mL | |
| 5 mM | 0.4229 mL | 2.1147 mL | 4.2294 mL | |
| 10 mM | 0.2115 mL | 1.0574 mL | 2.1147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA